Metformin Inhibits the Growth of Hypopharyngeal Squamous Cell Carcinoma of Fadu Cell and Down-Regulates LncAROD to Improve Prognosis
This finding presents a novel approach to the clinical management of HSCC, indicating that metformin influences various processes related to the growth and progression of HSCC. Specifically, it reduces lncAROD expression and inhibits tumor progression, suggesting that lncAROD may serve as a valuable biomarker for evaluating the prognosis of HSCC.
Authors
- Meiyu Liu (ORCID: https://orcid.org/0000-0002-4818-7092)
- Fang Liu (ORCID: https://orcid.org/0000-0002-1780-1723)
- Desheng Wang (ORCID: https://orcid.org/0000-0002-5844-0813)
Institutions
- Fujian Medical University (CN)
- Gannan Medical University (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2025-10-29
- DOI
- https://doi.org/10.2174/0118715206427268251006112304
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00